Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Christopher M Booth

Showing results (91-100 of 349) with videos related to

Pageof 35
Sort By:
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 2, 2019
Immunotherapy for Urothelial Cancer: Where Are the Randomized Trials?Francisco E Vera-Badillo, Ian F Tannock, Christopher M Booth
JAMA Oncology|August 26, 2021
Randomized Clinical Trials in the Era of Precision Oncology-The Role of End Points, Industry Funding, and Medical Writing Integrity-ReplyJoseph C Del Paggio, Elizabeth A Eisenhauer, Christopher M Booth
The Lancet. Oncology|January 1, 2022
Radiographic progression-free survival in the ACIS trial for prostate cancerIan F Tannock, Christopher M Booth, Bishal Gyawali, et al.
Eclinicalmedicine|November 29, 2022
Objective response rate of placebo in randomized controlled trials of anticancer medicinesArushi Sachdev, Isobel Sharpe, Meghan Bowman, et al.
Urologic Oncology|June 28, 2014
Patterns of referral for perioperative chemotherapy among patients with muscle-invasive bladder cancer: a population-based studyChristopher M Booth, David Robert Siemens, Yingwei Peng, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 30, 2024
Reply to D.J. Stewart et alChristopher M Booth, Elizabeth A Eisenhauer, Bishal Gyawali, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 21, 2023
Progression-Free Survival Should Not Be Used as a Primary End Point for Registration of Anticancer DrugsChristopher M Booth, Elizabeth A Eisenhauer, Bishal Gyawali, et al.
Journal of Hospital Medicine|December 17, 2010
Elements of confusionSumontra Chakrabarti, Christopher M Booth, Allan S Detsky, et al.
JAMA|February 19, 2004
Is this patient dead, vegetative, or severely neurologically impaired? Assessing outcome for comatose survivors of cardiac arrestChristopher M Booth, Robert H Boone, George Tomlinson, et al.
The Lancet. Oncology|October 5, 2023
Common Sense Oncology: including everyone - Authors' replyChristopher M Booth, Manju Sengar, Aaron Goodman, et al.
Pageof 35

Showing results (91-100 of 349) with videos related to

Sort By:
Pageof 35
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 2, 2019
Immunotherapy for Urothelial Cancer: Where Are the Randomized Trials?Francisco E Vera-Badillo, Ian F Tannock, Christopher M Booth
JAMA Oncology|August 26, 2021
Randomized Clinical Trials in the Era of Precision Oncology-The Role of End Points, Industry Funding, and Medical Writing Integrity-ReplyJoseph C Del Paggio, Elizabeth A Eisenhauer, Christopher M Booth
The Lancet. Oncology|January 1, 2022
Radiographic progression-free survival in the ACIS trial for prostate cancerIan F Tannock, Christopher M Booth, Bishal Gyawali, et al.
Eclinicalmedicine|November 29, 2022
Objective response rate of placebo in randomized controlled trials of anticancer medicinesArushi Sachdev, Isobel Sharpe, Meghan Bowman, et al.
Urologic Oncology|June 28, 2014
Patterns of referral for perioperative chemotherapy among patients with muscle-invasive bladder cancer: a population-based studyChristopher M Booth, David Robert Siemens, Yingwei Peng, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 30, 2024
Reply to D.J. Stewart et alChristopher M Booth, Elizabeth A Eisenhauer, Bishal Gyawali, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 21, 2023
Progression-Free Survival Should Not Be Used as a Primary End Point for Registration of Anticancer DrugsChristopher M Booth, Elizabeth A Eisenhauer, Bishal Gyawali, et al.
Journal of Hospital Medicine|December 17, 2010
Elements of confusionSumontra Chakrabarti, Christopher M Booth, Allan S Detsky, et al.
JAMA|February 19, 2004
Is this patient dead, vegetative, or severely neurologically impaired? Assessing outcome for comatose survivors of cardiac arrestChristopher M Booth, Robert H Boone, George Tomlinson, et al.
The Lancet. Oncology|October 5, 2023
Common Sense Oncology: including everyone - Authors' replyChristopher M Booth, Manju Sengar, Aaron Goodman, et al.
Pageof 35